Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 3/20 | 0.58 |
| ▸ | RARA | P10276 | 7/20 | 0.40 |
| ▸ | RARB | P10826 | 7/20 | 0.40 |
| ▸ | RARG | P13631 | 7/20 | 0.40 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.40 |
| ▸ | CYP26B1 | Q9NR63 | 2/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PTGES | O14684 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | RXRB | P28702 | 1/20 | 0.38 |
| ▸ | RXRG | P48443 | 1/20 | 0.38 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.38 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3020924 | 0.88 | CNR2 (0.71) | CNR2RARARARBRARGCYP26A1 | |
| SCHEMBL3009016 | 0.88 | CNR2 (0.53) | CNR2RARBRARGALOX5 | |
| SCHEMBL3016295 | 0.84 | CNR2 (0.80) | CNR2 | |
| SCHEMBL3020426 | 0.82 | CNR2 (0.58) | CNR2RARARARBRARGMEN1 | |
| SCHEMBL3009549 | 0.81 | CNR2 (0.52) | CNR2MEN1KMT2A | |
| SCHEMBL3019867 | 0.78 | CNR2 (0.71) | CNR2RARARARBRARGCYP26A1 | |
| SCHEMBL3021003 | 0.77 | CNR2 (0.66) | CNR2RARBRARGMEN1KMT2A | |
| SCHEMBL3017974 | 0.77 | CNR2 (0.78) | CNR2RARARARBRARGMEN1 | |
| SCHEMBL3016208 | 0.73 | CNR2 (1.00) | CNR2 | |
| SCHEMBL15428814 | 0.73 | CNR2 (1.00) | CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9394267-B2 | Heterocyclic modulators of cannabinoid receptors | THE CLEVELAND CLINIC FOUNDATION (US) | 2016-07-19 | — | — | US | disclosed |
| US-9339486-B2 | Heterocyclic modulators of cannabinoid receptors | THE CLEVELAND CLINIC FOUNDATION (US) | 2016-05-17 | — | — | US | disclosed |
| US-20150148408-A1 | HETEROCYCLIC MODULATORS OF CANNABINOID RECEPTORS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2015-05-28 | — | — | US | disclosed |
| EP-2178371-B1 | HETEROCYCLIC MODULATORS OF CANNABINOID RECEPTORS | UNIV TEXAS (US) | 2014-01-01 | — | — | EP | disclosed |
| US-20130237536-A1 | HETEROCYCLIC MODULATORS OF CANNABINOID RECEPTORS | THE CLEVELAND CLINIC FOUNDATION (US) | 2013-09-12 | — | — | US | disclosed |
| US-8440832-B2 | Heterocyclic modulators of cannabinoid receptors | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-05-14 | — | — | US | disclosed |
| US-20100204220-A1 | HETEROCYCLIC MODULATORS OF CANNABINOID RECEPTORS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2010-08-12 | — | — | US | disclosed |
| CN-101801187-A | heterocyclic modulators of cannabinoid receptors | UNIV TEXAS | 2010-08-11 | — | — | CN | disclosed |
| EP-2178371-A1 | HETEROCYCLIC MODULATORS OF CANNABINOID RECEPTORS | Board of Regents, The University of Texas System (US) | 2010-04-28 | — | — | EP | disclosed |
| WO-2009012221-A1 | HETEROCYCLIC MODULATORS OF CANNABINOID RECEPTORS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204220-A1 | HETEROCYCLIC MODULATORS OF CANNABINOID RECEPTORS | CNR1, CNR2, GPR18 | CNR2 2/4885RARA 1062/4885RARB 817/4885 |
| US-20130237536-A1 | HETEROCYCLIC MODULATORS OF CANNABINOID RECEPTORS | CNR1, CNR2, GPR18 | CNR2 2/4885RARA 1062/4885RARB 817/4885 |
| US-20150148408-A1 | HETEROCYCLIC MODULATORS OF CANNABINOID RECEPTORS | CNR1, CNR2, GPR18 | CNR2 2/4885RARA 1062/4885RARB 817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.